8-K 1 v235316_8k.htm FORM 8-K Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 

FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): September 21, 2011
 
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
         
Florida
  
001-33357
  
65-0643773
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
     
2 Snunit Street
  
20100
Science Park, POB 455
    
Carmiel, Israel
    
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code +972-4-988-9488
  
(Former name or former address, if changed since last report.)
 
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 7.01.  Regulation FD Disclosure
 
On September 21, 2011, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that Yossi Maimon, the Company’s Chief Financial Officer, will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27, 2011 at 11:20 AM BST at the Waldorf Hilton in London.  A copy of the press release is furnished as Exhibit 99.1.
 
The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01.  Financial Statements and Exhibits
 
(d)           Exhibits
 
99.1           Press release dated September 21, 2011
 

 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
PROTALIX BIOTHERAPEUTICS, INC.
   
Date: September 21, 2011 By:         /s/ David Aviezer                          
 
Name:    David Aviezer, Ph.D.
Title:      President and
               Chief Executive Officer
   
 
 
 
 
 
 
 
3